X

Trial Profile

A Multicenter and open-label clinical trial of efficacy and safety of Pomalidomide plus low-dose dexamethasone in patients with relapsed / refractory multiple myeloma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pomalidomide (Primary) ; Dexamethasone
Indications Multiple myeloma
Focus Therapeutic Use
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

21 Sep 2021 Results (n=74) assessing efficacy and safety of pomalidomide and dexamethasone (Pd) for Chinese patients with relapsed or refractory multiple myeloma, presented at the 46th European Society for Medical Oncology Congress.
06 Nov 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com